Supplementary Figure S15 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy

Supplementary Figure S15. Allogeneic rejection of ‘donor’ CD30.CAR with 4-1BB spacer (CD30.bb) EBVSTs occurs in mice engrafted with HLA-mismatched ‘recipient’ PBMCs in a cutaneous T cell lymphoma (CTCL) allorejection model. A, CD30, HLA-ABC and HLA-DRDPDQ expression on wildtype (WT) compared to human leukocyte antigen (HLA) class I and II knockout HuT 78 tumor cells by Crispr-Cas9 gene editing. B, Quantified bioluminescent signals of GFP-ffluc-expressing CD30.bb EBVSTs at the tumor sites in the presence (black line) or absence (grey line) of ‘recipient’ PBMCs. The graph denotes mean + SD.